CLL Microlearning Series – Video #4: Practical Aspects of Prescribing Zanubrutinib
Practical Aspects of Prescribing Zanubrutinib
This video covers the key practical details clinicians should know when prescribing zanubrutinib. As a second-generation BTK inhibitor, it offers effective disease control with a flexible dosing schedule that can be tailored to patient needs.
An APP specializing in CLL walks through how dosing options, adjustments, and real-world considerations help support safe and consistent use of the medication.
In This Video, You’ll Learn:
- Standard zanubrutinib dosing (320 mg once daily or 160 mg twice daily)
- How tablet formulation supports simple dose reductions
- Dose adjustments for hepatic impairment or CYP3A interactions
- Ways dosing flexibility can improve adherence
- The role of APPs in identifying side effects or medication changes that require dose modification